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Abstract
Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial 
function and have been shown to be elevated in women with polycystic ovary syndrome 
(PCOS). It remains poorly understood how pharmacological options for managing PCOS 
affect EMP levels.
Objective: To characterise and compare the effects of empagliflozin vs metformin on the 
circulating levels of EMPs in overweight/obese women with PCOS.
Methods: This was a randomised, comparative, 12-week single-centre trial conducted at 
the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This 
analysis includes data from 39 overweight/obese women with PCOS who completed the 
study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 
mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment 
and analysed for specific surface proteins (ICAM-1, VCAM-1, PECAM-1, E-selectin and 
endoglin) expressed by circulating EMPs using flow cytometry.
Results: In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 
(P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes 
were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, 
VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, whereas 
all other EMPs remained unchanged. When data were expressed as percentage change 
from baseline in each group, no significant differences were seen between groups for 
any biomarker (P-values from 0.22 to 0.80).
Conclusions: Short-term administration of empagliflozin and metformin in overweight/
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Polycystic ovary syndrome (PCOS) is a common 
endocrinopathy, affecting up to one in five women of 
reproductive age (1). In addition to its cardinal features of 
hyperandrogenism, menstrual irregularities and polycystic 
ovaries, PCOS is associated with obesity, insulin resistance, 
dyslipidaemia and chronic systemic inflammation, all of 
which put women with PCOS at risk of cardiovascular (CV) 
disease (1, 2). Indeed, there is evidence that women with 
PCOS are at risk of developing subclinical atherosclerosis 
even at a young age (3, 4). Endothelial dysfunction is an 
early indicator of the atherosclerotic process, and several 
studies have demonstrated abnormal endothelial function 
assessed by flow-mediated dilation and peripheral arterial 
tonometry (Endo-PAT) in PCOS (5, 6, 7). Treatments that 
enhance endothelial function can potentially delay the 
progression of atherosclerosis and, ultimately, lessen the 
risk of future CV events (8).
Endothelial microparticles (EMPs) are extracellular 
vesicles formed by membrane blebbing of activated or 
apoptotic endothelial cells and packaging of proteins, 
some of which are established markers of endothelial 
injury such as PECAM-1, intercellular adhesion molecule 1 
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), 
E-selectin, endoglin and vascular endothelial growth 
factor (VEGF) (9, 10, 11, 12, 13). Techniques to measure 
EMPs rely on the preparation of platelet-free plasma 
and subsequent identification of cell-surface proteins 
(e.g. PECAM, ICAM-1 and E-selectin) (13). In addition 
to their microparticle-bound form, these cell-surface 
proteins can also be measured in their soluble from in 
serum samples (13). EMPs synthesis is stimulated by 
inflammatory cytokines, reactive oxygen species (ROS), 
lipopolysaccharides, thrombin and low shear stress. In 
turn, by facilitating the interactions of endothelial cells 
with immune cells, EMPs are involved in endothelial 
cell modifications, inflammation, coagulation and 
angiogenesis (9, 10, 11, 12, 13). Elevated EMP levels have 
been associated with cardiovascular and autoimmune 
diseases, cancer, endocrine and metabolic disorders 
and, therefore, they are often used as surrogate markers 
of endothelial dysfunction in these conditions (14). 
Compared to controls, women with PCOS have increased 
levels of circulating MPs deriving from endothelial 
cells, platelets and leukocytes (15, 16, 17, 18). Lifestyle 
interventions (e.g. exercise and dietary energy restriction) 
may be promising in reducing inflammatory markers 
including EMPs assessed in platelet-free plasma or 
their cell-surface proteins measured in serum (19, 20). 
Few available studies on the effects of pharmacological 
agents for PCOS management on the EMP levels 
have yielded mixed results. For example, hormonal 
contraceptives, which are often prescribed to manage 
hyperandrogenism and menstrual disturbances in this 
population, have been shown to increase serum ICAM-1 
(21). Metformin, which may exert beneficial effects on 
insulin resistance and hyperinsulinaemia in PCOS (22), 
has been shown to reduce ICAM-1 (23), VCAM-1 (18), 
E-selectin (23) and tissue factor levels in serum samples 
(24). Similarly, our recent study showed that treatment 
with exenatide resulted in reductions in serum ICAM-1, 
p-selectin and e-selectin, although no pronounced 
changes were seen in endothelial function (25).
Empagliflozin is a sodium-glucose cotransporter 2 
(SGLT-2) inhibitor used in the treatment of type 2 
diabetes. SGLT-2 inhibitors act by inhibiting glucose 
reabsorption by the kidney and, therefore, they result 
in mild glycosuria and net caloric loss (26). SGLT-2 
inhibitors have been demonstrated to reduce weight, 
improve arterial stiffness and vascular resistance and 
decrease the relative risk for cardiovascular and all-cause 
mortality in patients with type 2 diabetes (27, 28). In the 
first study comparing the effects of empagliflozin and 
metformin in overweight/obese women with PCOS, we 
demonstrated that empagliflozin treatment over 12 weeks 
resulted in significant improvements in anthropometric 
parameters and body composition, without overt changes 
in hormonal or metabolic parameters (29).
The aim of this analysis was to explore and compare 
the effects of empagliflozin and metformin on a panel of 
EMPs bearing proteins with established roles in endothelial 
injury (13) in overweight/obese women with PCOS. Given 
that empagliflozin and metformin have been shown to 
exert positive effects on cardiovascular risk factors (27, 
28, 30, 31, 32), with these effects potentially mediated 
by amelioration in inflammation and endothelial injury 
(30, 31, 32, 33, 3, 35, 36), we hypothesised that both 
treatments would result in reductions in EMP levels
Materials and methods
This is a secondary analysis of an open-label, randomised 
study which compared the effects of empagliflozin 
and metformin in overweight/obese women with 
PCOS. This study was approved by the Medicines and 
Healthcare Products Regulatory Authority (MHRA) (Ref: 
21411/0254/001-0001), the Yorkshire & Humber Health 
Research Authority and Leeds East Research Ethics 
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Committee (REC reference: 17/YH/0118), registered at 
www.clinicaltrials.gov (NCT03008551) and conducted in 
the Academic Diabetes, Endocrinology and Metabolism 
Research Centre at Hull Royal Infirmary. All participants 
gave their informed consent in writing.
Inclusion/exclusion criteria and study procedures 
have been explained in detail (29). In brief, all women aged 
between 18 and 45 years, had a BMI ≥25 kg/m2 and were 
diagnosed with PCOS according to the Rotterdam criteria 
(37). Exclusion criteria were differential diagnoses of non-
classical 21-hydroxylase deficiency, hyperprolactinaemia, 
Cushing’s disease and androgen-secreting tumours, 
pregnancy or intention to become pregnant, breastfeeding, 
documented use of oral hormonal contraceptives and 
hormone-releasing implants, metformin or other insulin-
sensitizing medications, clomiphene citrate or oestrogen 
modulators, gonadotropin-releasing hormone modulators 
and Minoxidil, diagnosis of diabetes, history or presence of 
malignant neoplasms within the last 5 years, pancreatitis 
(acute or chronic), recurrent urinary tract infections or 
gastrointestinal tract surgery, ongoing, inadequately 
controlled thyroid disorder and known hypersensitivity 
to the investigational medicinal products or any of their 
excipients.
PCOS patients received either empagliflozin 
25 mg (Jardiance) or metformin SR 1500 mg (Bolamyn) 
per day over a 12-week period. Evaluations were 
performed at baseline and after 12 weeks of treatment. 
Examination included anthropometric (weight, BMI, 
waist circumference (WC) and hip circumference (HC)) 
and body composition assessments and an endothelial 
function measurement – detailed description of these 
measurements is provided in 29. Blood samples were 
collected at these time points and analysed for EMPs. 
Additional biochemical analyses included measurement 
of reproductive hormones and cardio-metabolic 
parameters (fasting glucose, fasting insulin, HOMA-IR, 
total cholesterol, LDL-C, HDL-C, triglycerides (TG) and 
hs-CRP): these results have been presented in our previous 
work (29).
Endothelial function was assessed using Endo-PAT 
2000 (Itamar Medical Ltd, Caesarea, Israel). Participants 
relaxed for at least 15 min in a quiet, controlled temperature 
(22–24°C) room. Endo-PAT biosensors were positioned 
on the index fingers of both hands. For this assessment, 
subjects were asked to avoid talking or moving. The 
probes were inflated, and the signals were recorded on the 
computer according to manufacturer’s instructions. The 
assessment comprised of: (1) baseline recording (0–5 min), 
(2) blood pressure cuff inflation to a supra-systolic level 
(at least 60 mmHg above systolic pressure and not ≥200 
mmHg) (5–10 min), and (3) blood pressure cuff deflation 
and recording of Endo-PAT readings (10–15 min). Output 
variables included the reactive hyperaemia index (RHI), a 
measure for endothelial function and the augmentation 
index (AI), a measure for arterial stiffness.
EMP assessment and characterisation
To prepare platelet-free plasma (within 2 h of blood 
drawing), blood samples were centrifuged at 1000 g for 
10 min and the supernatant was further centrifuged at 
12,000 g for 10 min. All assays were performed on a BD 
Accuri™ C6 Plus flow cytometer (BD Biosciences). The 
platelet-free plasma samples (25 μL) together with 5 μL 
of fluorescin isothyocynate conjugated monoclonal 
antibodies against cell-type specific antigens were 
incubated for 30 min in darkness. EMPs were identified 
using platelet endothelial cell adhesion molecule-1 
(PECAM-1 or CD31) (BD Biosciences); intercellular 
adhesion molecule 1 (ICAM-1 or CD54) (Bio-Rad), 
E-selectin (or CD62-E) (Bio-Rad); endoglin (or CD105) 
(BD Biosciences) and vascular cell adhesion molecule 1 
(VCAM-1 or CD106) (BD Biosciences). After incubation, 
the samples were diluted in 300 μL of PBS that had been 
filtered through a sterile 0.1-µm syringe filter (Minisart™, 
Nottingham, UK). A total of 25 μL of counting beads with 
an established concentration (AccuCheck Counting Beads, 
Life Technologies Corporation) were added to each sample 
to calculate EMPs as absolute numbers per microliter.
Statistical analysis
All variables were checked for normality using the Shapiro–
Wilk test and for extreme outliers (>3 times interquartile 
range (IQR) above the third quartile or <3 times IQR below 
the first quartile) graphically. Participants indicated as 
extreme outliers for each EMP were excluded from analysis. 
Within-group comparisons between baseline and 12-week 
follow-up were performed using a paired t-test or a signed-
rank test for normally and non-normally distributed data. 
For between-group comparisons, data were expressed as 
percentage change from baseline and analysed using an 
independent t-test or Mann–Whitney U-test for normally 
and non-normally distributed data. Correlations between 
changes in EMPs and Endo-PAT measures were examined 
using Spearman’s correlations. Values are presented as 
median and interquartile range. Two-tailed analyses were 
performed using IBM-SPSS version 24.0 with statistical 
significance set at P ≤ 0.05.
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The baseline anthropometric characteristics, hormonal and 
metabolic profile of the participants in the empagliflozin 
(n = 19, age: 26.0 (8.0) years, BMI: 37.1 ± 6.2 kg/m2) and 
the metformin (n = 20, age: 31.5 (9.0) years, BMI: 38.7 ± 7.8 
kg/m2) groups have been presented previously (29).
In the empagliflozin group, ICAM-1 (P = 0.006), 
E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs 
increased significantly following 12 weeks of treatment, 
but no changes were seen in PECAM-1 (P = 0.93) or 
endoglin (P = 0.13) EMPs (Table 1). In the metformin 
group, VCAM-1 (P < 0.001) EMPs significantly increased 
after 12 weeks of treatment, whereas all other EMPs 
remained unchanged (Table 1).
When data were expressed as percentage change 
from baseline in each group, no significant differences 
were seen between the treatment groups for any marker 
(P-values from 0.22 to 0.80) (Table 1.).
As we reported in 29, endothelial function determined 
by Endo-PAT did not change following treatment with 
empagliflozin (RHI; baseline: 1.6 (0.5), 12 weeks: 1.5 (0.7), 
AI; baseline: −3.0 (17.0), 12 weeks: −4.0 (20.0)) or 
metformin (RHI; baseline: 1.7 (0.6), 12 weeks: 1.6 (0.5), 
AI; baseline: 0.5 (14.0), 12 weeks: 0.5 (19.5)). There were 
no significant correlations between EMP changes and 
changes in Endo-PAT measures in the empagliflozin or 
metformin group (all P values >0.05).
Discussion
This study characterised and compared the effects of 
empagliflozin vs metformin on EMPs in overweight/
obese women with PCOS. Contrary to our hypothesis, 
within-group comparisons revealed increases in ICAM-1, 
E-selectin and VCAM-1 EMPs following a 12-week 
treatment period with empagliflozin, whereas treatment 
with metformin resulted in increases in VCAM-1 EMPs 
only. Between groups comparisons did not show any 
differences in any of these markers, suggesting a similar 
pattern of changes in both treatment arms. These results 
consistently indicate activation of endothelial cells with 
empagliflozin and metformin.
Few studies on the impact of pharmacological 
management options for PCOS on EMP levels have 
yielded mixed results. Diamanti-Kandarakis et al. showed 
a reduction in soluble VCAM-1 levels independent of 
BMI changes after 6 months of metformin administration 
(1700 mg/day) (18). In the same study, metformin did not 
result in changes in soluble ICAM-1 and E-selectin (18). 
In contrast, reduction in serum ICAM-1 and E-selectin 
were reported in a 12-week intervention with metformin 
(increasing daily dose from 500 to 1500 mg) (23). A 
cross-sectional study demonstrated lower total MPs and 
tissue factor in women with PCOS using metformin 
(2 × 850 mg/day) for at least 6 months (24). These 
discrepant results may be largely due to differences in 
metformin treatments (i.e. duration) and participants’ 
characteristics (age, BMI, insulin resistance or other 
metabolic conditions). Importantly, the results from 
these previous investigations (18, 23, 24) are not directly 
comparable to our findings. This is because we assessed 
changes in EMPs bearing PECAM-1, ICAM-1, E-selectin, 
endoglin and VCAM-1, rather than changes in the serum 
concentrations of these surface proteins. The increase 
in VCAM-1 EMPs following 12 weeks of treatment with 
metformin in our study suggests that VCAM-1 may be 
selectively packaged into EMPs at the cost of its soluble 
release or that the VCAM-1 expression on the endothelial 
cells is increased, thus increasing the probability of 
VCAM-1 becoming incorporated into EMPs. If soluble 
VCAM-1 is decreased (18), this may be due to preferential 
VCAM-1 packaging into EMPs. We have previously 
shown that the Endoglin:VCAM-1 EMP ratio was shifted 
to a more VCAM-1 dominant profile in women with 
PCOS (38).
Table 1 Changes in circulating EMPs following 12 weeks of treatment with empagliflozin and metformin.
Empagliflozin (n = 19) Metformin (n = 20)
Baseline 12 weeks %baseline change Baseline 12 weeks %baseline change
PECAM-1 536 (274)c 581 (242) 6.9 (72.3)c 529 (171)b 426 (336) −13.7 (69.3)
ICAM-1 999 (717)c 1597 (931)a 52.3 (106.1)c 785 (872)b 1351 (787) 54.9 (150.5)
E-selectin 681 (460)c 1055 (520)a 52.2 (103.8)c 677 (502) 935 (511) 32.2 (114.5)
Endoglin 153 (91)c 120 (63) −28.5 (61.2)c 132 (39)b 106 (87) −19.0 (60.6)
VCAM-1 199 (179) 426 (143)a 62.6 (102.2) 229 (98) 451 (267)a 82.2 (99.0)
Data are presented as median (interquartile range).
aP < 0.05, significant difference from baseline within treatment group; bAnalysis performed in 19 participants; cAnalysis performed in 18 participants.
ICAM-1, intercellular adhesion molecule 1; PECAM-1, endothelial cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule 1.
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There are no comparative studies on the effects of 
empagliflozin on EMP levels in PCOS. A study using 
another SGLT-2 inhibitor, canagliflozin, did not result in 
alterations in serum VCAM-1 levels in patients with type 
2 diabetes (39). In the present analysis, the simultaneous 
increases in ICAM-1, E-selectin and VCAM-1 EMPs indicate 
endothelial cell activation and enhanced interactions 
between endothelial and other immune cells. Specifically, 
ICAM-1 is an adhesion molecule, which regulates vascular 
permeability by facilitating leukocytes rolling within 
vasculature and by promoting leukocytes-endothelium 
interrelationships (40). E-selectin allows the binding of 
neutrophils, monocytes and T-cell subpopulations to sites 
of vascular injury and promotes angiogenesis. VCAM-1 is 
another adhesion molecule, which mediates leukocytes 
rolling and adhesion to the endothelium, regulates 
leukocytes transendothelial migration and modulates 
endothelial signalling through the activation of NADPH 
oxidase and formation of ROS (41, 42).
Increasing evidence suggests that the role of EMPs 
is more complex than initially perceived and that it is 
unclear whether EMPs-mediated alterations are part of 
physiological vascular homeostasis or if they contribute 
to pathological conditions (10, 11, 12). In our study, there 
was no evidence of endothelial impairment (Endo-PAT) in 
response to treatment with empagliflozin or metformin. As 
such, it is uncertain whether the increases in endothelial 
markers represent a transitory, adaptive response to 
regenerate the endothelium, limit vascular damage and 
restore homeostasis or if they contribute to endothelial 
dysfunction and increased CVD risk in the longer-term 
(11). The discordant results of the adhesion molecules 
assessed in serum and the direct measures of endothelial 
measures have been reported previously (25). Our findings 
indicate that biochemical markers of endothelial function 
change early during an intervention, whereas functional 
measures may need more time to be altered. Longer-time 
studies with concurrent measurements of endothelial 
markers and direct measures of endothelial function are 
required to provide further insights into the relationship 
of these assessments.
Although the long-term CVD risk following 
empagliflozin and metformin treatment remains to be 
determined in PCOS, studies using these drugs support 
cardioprotective effects in patients without PCOS. The 
EMPA-REG OUTCOME trial revealed that empagliflozin 
given in addition to standard care reduced the risk of 
CV death by 38% and heart-failure hospitalisation by 
35% in patients with type 2 diabetes (27). Among other 
mechanisms, the authors mentioned that improvements 
in arterial stiffness may contribute to this CVD risk 
reduction (27). Similar cardio- and reno-protective effects 
relative to placebo were demonstrated after treatment 
with canagliflozin in patients with type 2 diabetes and 
a history of CVD or >2 CVD factors (43). In agreement 
with human studies, preclinical studies in diabetic or 
prediabetic animals have demonstrated reductions in 
oxidative stress, inflammatory cytokines and vascular 
dysfunction following treatment with SGLT-2 inhibitors 
(33, 34, 35, 36). Similarly, an increasing number of studies 
support that metformin exerts cardioprotective effects 
in patients with and without diabetes (30). Mechanistic 
studies have demonstrated that the cardioprotective 
effects of metformin may be explained by its reducing 
endoplasmic reticulum (ER) and oxidative stress effects, 
anti-atherogenic, anti-inflammatory action, protection 
from endothelial injury and favourable effects on blood 
lipids (30, 31, 32).
The current analysis is strengthened by its design 
and the assessment of a panel of EMPs indicative of 
endothelial cell activation and apoptosis. This study was 
powered to detect difference in hs-CRP (29); therefore, 
a limitation of the present analysis is the lack of pre-
specified statistical testing due to its post-hoc nature. 
Data from a control group would be informative on 
whether EMP levels change due to PCOS per se; however, 
such data are unavailable in this analysis. Given the high 
prevalence of menstrual-cycle disorders in women with 
PCOS, including amenorrhea and oligomenorrhea, we 
were unable to adjust for this parameter in the current 
intervention. Although there is the suggestion that 
EMP may be affected by the menstrual cycle (44), this 
requires clarification and confirmation. The assessment 
of additional markers indicative of endothelial function 
and systemic inflammation (endothelin-1, angiotensin 
II, ROS, TNF (TNF-a) or interleukin (IL)-1 or 6) were not 
performed as part of this study, but their future evaluation 
could provide insights into the mechanism actions of 
metformin and empagliflozin in this population. Finally, 
the duration of the present study is short (12 weeks) 
and it is possible that treatments over longer periods are 
required to have differential effects on EMP levels or direct 
measures of endothelial function.
Conclusions
In summary, treatment with empagliflozin and metformin 
for over 12 weeks in obese women with PCOS increased 
levels of EMPs, which are likely to be expressed by 
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endothelial cells during their activation. We did not show 
alterations in direct measures of endothelial function 
(Endo-PAT) with either treatment, suggesting that 
surrogate markers precede or do not reflect endothelial 
function changes in this population. Further longer-
term, placebo-controlled and comparative-treatment 
pharmacological trials are required to confirm these 
findings and elucidate the mechanisms that contribute 
to the observed EMP changes and their relationship with 
clinical outcomes in diverse PCOS populations.
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